Results 201 to 210 of about 1,690,454 (303)

A Systematic Comparison of Alpha‐Synuclein Seed Amplification Assays for Increasing Reproducibility

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Seed amplification assays (SAAs) enable ultrasensitive detection of misfolded α‐synuclein across biofluids and tissues. Yet, heterogeneity in protocols limits cross‐study comparability and clinical translation. Here, we review α‐synuclein SAA methods and their performance across various biological matrices.
Manuela Amaral‐do‐Nascimento, Daniela F. Santos, Tuane C. R. G. Vieira, Tiago F. Outeiro   +3 more
wiley   +1 more source

Co-benefits of health: from evidence to governance, politics and advocacy. [PDF]

Eur J Public Health
Marchandise C, Falkenbach M, Siciliani L, Greer SL, Wismar M.   +4 more
europepmc   +1 more source

MACROECONOMIC POLICY AND COLLECTIVE ACTION [PDF]

David Colander
core  

The Future of Employee Collective Action Waivers [PDF]

, 2018
Smith, Douglas O.
core   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

A megastudy of behavioral interventions to catalyze public, political, and financial climate advocacy. [PDF]

PNAS Nexus
Goldwert D, Constantino SM, Patel Y, Sabherwal A, Semken C, Brick C, Castiglione A, Debnath R, Doell KC, Dubey R, Fang K, Goldberg MH, Ma WJ, Nielsen KS, Rathje S, Schneider CR, Sheldrick M, Shreedhar G, van der Linden S, Acevedo J, Alam R, Boon-Falleur M, Buchel O, Chen X, Cheng PW, Fabre A, Feinberg M, Frese J, Fuller K, Helferich M, Kantorowicz J, Kantorowicz-Reznichenko E, Kim A, Kim JJH, Lee J, Marchewka A, Mildenberger M, Pearson A, Pezzuto JH, Pizziol V, Prokosch M, Protzko J, Ramos GA, Rose W, Sherman DK, Swanson E, Syropoulos S, Tavoni A, Thiel MH, Van Boven L, Willer R, Yang T, Zaremba D, Vlasceanu M.   +53 more
europepmc   +1 more source

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

Developing Measures of Watershed Knowledge. [PDF]

Environ Manage
Mainzer S, Dillard JP.
europepmc   +1 more source

Anti‐CD19 CAR T Cells in Autoimmune Encephalitis: Inflammation Controlled, Neurodegeneration Unchecked?

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Just recently, successful chimeric antigen receptor (CAR) T cell therapy was reported in the first patient with refractory, anti‐diacylglycerol lipase alpha (DAGLA) antibody‐mediated autoimmune encephalitis, achieving partial clinical remission.
Dimitrios Mougiakakos, Marwa Al‐Dubai, Denise Walther, Dominic Borie, Jan D. Lünemann, Marc Pawlitzki, Sven G. Meuth, Solveig Henneicke, Stefan Vielhaber, Stefanie Schreiber   +9 more
wiley   +1 more source

Understanding Agency in Woman's Economic Empowerment Policy: an Analysis of Three Programs in India. [PDF]

Gates Open Res
Ambast S, Khare P, Patwardhan V, McDougal L, Hay K.   +4 more
europepmc   +1 more source